Pralatrexate 20 mg/mL
Pralatrexate · INJECTION · Dr.Reddy's Laboratories Inc.,
Pralatrexate is a injection containing pralatrexate at 20 mg/mL, taken intravenous. Manufactured by Dr.Reddy's Laboratories Inc.,.
Key Facts
- Brand Name
- Pralatrexate
- Generic Name
- Pralatrexate
- NDC Code (Product)
43598-342- Manufacturer
- Dr.Reddy's Laboratories Inc.,
- Strength
- 20 mg/mL
- Dosage Form
- INJECTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- ANDA206183
- Drug Class
- Folate Analog Metabolic Inhibitor [EPC]
- Marketing Start
- 03/04/2026
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Full Prescribing Information
Indications & Usage
1 INDICATIONS AND USAGE Pralatrexate injection is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on overall response rate [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Pralatrexate injection is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )
Dosage & Administration
2 DOSAGE AND ADMINISTRATION Supplement patients with vitamin B 12 mg intramuscularly every 8-10 weeks starting 10 weeks before the first dose and folic acid 1 to 1.25 mg orally once daily starting 10 days before the first dose. ( 2.1 ) The recommended dosage of Pralatrexate injection is 30 mg/m 2 intravenously over 3 to 5 minutes once weekly for 6 weeks in 7-week cycles. ( 2.1 ) For patients with severe renal impairment (GFR 15 to 29 mL/min/1.73 m 2 ), reduce the Pralatrexate injection dose to 15 mg/m 2 ( 2.1 ). 2.1 Important Dosing Information Pretreatment Vitamin Supplementation Folic Acid Instruct patients to take folic acid 1 to 1.25 mg orally once daily beginning 10 days before the first dose of Pralatrexate injection. Continue folic acid during treatment with Pralatrexate injection and for 30 days after the last dose [see Warnings and Precautions ( 5.1 , 5.2 )]. Vitamin B 12 Administer vitamin B 12 1 mg intramuscularly within 10 weeks prior to the first dose of Pralatrexate injection and every 8-10 weeks thereafter. Subsequent vitamin B 12 injections may be given the same day as treatment with Pralatrexate injection [see Warnings and Precautions ( 5.1 , 5.2 )]. 2.2 Recommende…
Contraindications
4 CONTRAINDICATIONS None None. ( 4 )
Drug Interactions
7 DRUG INTERACTIONS Avoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. If coadministration is unavoidable, monitor for increased risk of adverse reactions. ( 7.1 ) 7.1 Effects of Other Drugs on Pralatrexate Injection Coadministration of Pralatrexate injection with probenecid increased pralatrexate plasma concentrations [see Clinical Pharmacology ( 12.3 )] , which may increase the risk of adverse reactions. Avoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. If coadministration is unavoidable, monitor for increased risk of adverse reactions.
Adverse Reactions
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Myelosuppression [see Warnings and Precautions ( 5.1 )] Mucositis [see Warnings and Precautions ( 5.2 )] Dermatologic Reactions [see Warnings and Precautions ( 5.3 )] Tumor Lysis Syndrome [see Warnings and Precautions ( 5.4 )] Hepatic Toxicity [see Warnings and Precautions ( 5.5 )] Most common adverse reactions (>35%) are mucositis, thrombocytopenia, nausea, and fatigue. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Peripheral T-cell Lymphoma The safety of Pralatrexate injection was evaluated in Study PDX-008 [see Clinical Studies ( 14 )]. Patients received Pralatrexate injection 30 mg/m 2 once weekly for 6 weeks in 7-week cycles. The median duration of treatment was 70 days (r…
Frequently Asked Questions
What is Pralatrexate used for?
Pralatrexate contains Pralatrexate. It is a injection taken intravenous. Consult your doctor for specific uses.
Is Pralatrexate a controlled substance?
Pralatrexate is not classified as a controlled substance by the DEA.
What is the generic name for Pralatrexate?
The generic name for Pralatrexate is Pralatrexate. There are 2 other brand versions of Pralatrexate.
What is the NDC code for Pralatrexate 20 mg/mL?
The NDC (National Drug Code) for Pralatrexate 20 mg/mL is 43598-342, listed by Dr.Reddy's Laboratories Inc.,.